Cagrilintide – 10mg

Cagrilintide is an innovative, synthetic, long-acting analog of the pancreatic hormone amylin. It serves as a dual agonist targeting both amylin and calcitonin receptors, which are crucial regulators of metabolic homeostasis and appetite signaling. Engineered via strategic amino acid substitutions to prevent amyloid fibril formation and lipidated with a fatty diacid sidechain, Cagrilintide displays high stability and an extended half-life. It is widely used in preclinical laboratory research to evaluate multi-pathway approaches to metabolic regulation and synergistic energy balance. [1, 2, 3, 4, 5, 6, 7]

Key Features & Characteristics

• Mechanism of Action: Dual agonist that binds selectively to amylin and calcitonin receptors to modulate central metabolic pathways. [1, 2]
• Structural Optimization: Modified peptide scaffold incorporates specific proline substitutions to inhibit deamination and eliminate fibril accumulation. [1, 2]
• Extended Pharmacokinetics: Features acylation with a C-20 fatty diacid spacer, enabling reversible albumin binding and prolonged experimental viability. [1]
• Physical Form: Typically synthesized via high-fidelity solid-phase peptide synthesis (SPPS) and supplied as a highly purified lyophilized powder. [1]

Primary Research Applications

• Satiety & Satiation Pathways: Investigated for its direct action on the brainstem and hypothalamus to induce fullness signals independent of standard GLP-1 pathways. [1]
• Gastric & Glucagon Dynamics: Studied for its role in decelerating gastric emptying rates and suppressing postprandial glucagon secretion to manage glucose spikes. [, 2]
• Synergistic Combination Modeling: Frequently evaluated alongside GLP-1 receptor agonists (such as semaglutide) to explore non-duplicative, additive effects on caloric intake and weight reduction models. [1, 2]

For Research Use Only. Not for human consumption, therapeutic, or diagnostic use.